

Joint session of the
Nonprescription Drugs Advisory Committee
and the
**Advisory Committee for
Reproductive Health Drugs**

December 16, 2003

NDA 21-045 - proposing over-the-counter (OTC) use of Plan B®
(levonorgestrel)

Index

- | | |
|-------|--|
| Tab 1 | <u>Meeting Agenda, including Discussion Points to Consider</u> |
| Tab 2 | Review of the Plan B® OTC Label Comprehension Study <ul style="list-style-type: none">◆ <u>Review from the Division of Surveillance, Research and Communication Support</u>◆ <u>Medical Officer Review</u> |
| Tab 3 | Review of the Actual Use Study <ul style="list-style-type: none">◆ <u>Executive Summary</u>◆ <u>Summary of Results of Actual Use of Low Comprehension Concepts from the Label Comprehension Study</u>◆ <u>Plan B® OTC Actual Use Study</u> |
| Tab 4 | Review of Behavior Study Literature <ul style="list-style-type: none">◆ <u>Sexual and Contraceptive Behavior Studies on Plan B®</u> |
| Tab 5 | <u>Plan B Safety Review</u> <ul style="list-style-type: none">◆ <u>Medical Officer Review</u>◆ <u>Office of Drug Safety, Division of Drug Risk Evaluation Review</u>◆ <u>Review of Teratogenic Risk of Hormonal Products for Contraception</u> |
| Tab 6 | <u>Draft Label</u> |
| Tab 7 | (to be distributed the first week of December)
Overview of existing and potential non-prescription distribution mechanisms |